利格列汀对二甲双胍联合吡格列酮控制不佳的2型糖尿病治疗效果

Effect of Linagliptin on the Bad Controlled Patients with Type 2 Diabetes after Melbine and Pioglitazone

目的研究利格列汀对二甲双胍联合吡格列酮控制不佳的2型糖尿病治疗的作用。方法选取2015年1月—2017年5月收治的56例经二甲双胍联合吡格列酮治疗效果不佳2型糖尿病患者,随机分为观察组、对照组,观察两组空腹血糖、餐后2 h血糖、HbA1c、HOMA-IR变化。结果治疗后观察组FBG、2 hPG、HbA1c均低于对照组,HOMAIR也低于对照组,不良反应发生率仅为3.57%,远较对照组的17.86%低,两组差异有统计学意义(P<0.05)。结论利格列汀对二甲双胍联合吡格列酮控制不佳的2型糖尿病治疗效果良好,能有效控制血糖水平。

Objective To research the effect of linagliptin on the bad controlled patients with type 2 diabetes after melbine and pioglitazone. Methods 56 cases of bad controlled patients with type 2 diabetes after melbine and pioglitazone admitted and treated in our hospital from January 2015 to May 2017 were randomly divided into two groups, and the changes of fasting blood glucose, postprandial 2 h blood glucose, HbA1c, HOMA-IR of the two groups were observed. Results After treatment, the FBG, 2 hPG, HbA1c in the observation group were lower than those in the control group, and the HOMA-IR was lower than that in the control group, and the incidence rate of adverse reactions was much lower than that in the control group（3.57% vs 17.86%）, and the difference was statistically significant（P〈0.05）. Conclusion The effect of linagliptin on the bad controlled patients with type 2 diabetes after melbine and pioglitazone is good, which can effectively control the blood glucose level.